Share Name Share Symbol Market Type Share ISIN Share Description
AstraZeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -45.00p -0.99% 4,517.00p 4,516.50p 4,517.50p 4,561.50p 4,517.00p 4,560.00p 217,386.00 08:17:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,627.4 2,876.5 224.3 20.3 57,139.32

AstraZeneca Share Discussion Threads

Showing 10251 to 10269 of 10275 messages
Chat Pages: 411  410  409  408  407  406  405  404  403  402  401  400  Older
DateSubjectAuthorDiscuss
21/2/2017
10:19
21st feb Berenberg 'buy' tp 5450p cut from 5500p
philanderer
17/2/2017
09:38
17th feb Jefferies buy tp 5250p up from 4800p
philanderer
15/2/2017
17:22
China MediTech And AstraZeneca Plc (NYSE: AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017 HTTPS://marketexclusive.com/china-meditech-astrazeneca-plc-nyse-azn-present-savolitinib-phase-ii-results-genitourinary-cancers-symposium-2017/72288/
philanderer
15/2/2017
14:13
xd tomorrow morning for the 150p dividend
philanderer
15/2/2017
12:13
Will these recover after divi is payed ?
stevenrevell
14/2/2017
14:04
I guess Liberum hasn't been paying attention to the way in which immunoncology has panned out for BMS. It is, indeed, high risk. I think the market has, to some extent, priced that in. AZN under the new CEO has resurrected some of the previously shuttered research that might lead to effective cancer treatments but it has some way to go and they won't be blockbuster treatments in the way that the old ones were: they will be highly targeted and so naturally have a smaller potential market per treatment or combination of treatments.
echolocator
14/2/2017
09:20
Liberum: AstraZeneca has further to go ‘Gross mis-pricing’ of AstraZeneca (AZN) shares is over but Liberum sees another 10% in upside. Analyst Roger Franklin retained his ‘buy’ recommendation but reduced the target price from £52.00 to £51.00. The shares were trading up 0.4%, or 18p, at £46.45 at the time of writing. ‘We upgraded AstraZeneca at the end of November, concluding that the valuation priced little to nothing for the high potential immuno-oncology franchise,’ he said. ‘With the attractive valuation and reassurance from management on unchanged [lung cancer study] Mystic confidence, the stock is now up 10%. While the gross mispricing is now over, even after modestly trimming our price target on weak earnings, we do see another c.10% upside to our fair value with several catalysts to come pre-Mystic. ‘But the real prize is the high-risk/high-reward potential for immuno-oncology to work in all comers and across multiple-indicators, at which point AstraZeneca is a £60-plus stock in our view.’ HTTP://citywire.co.uk/money/the-expert-view-hargreaves-lansdown-capita-and-dfs/a991816?re=44808&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=5
philanderer
13/2/2017
18:06
Have tbh, thought we were going under £40 here, just a little wrong!. It's approx 2% of what I have invested so s welcome development.
essentialinvestor
13/2/2017
11:33
Fairly tough resistance here (see main chart in header).
tim 3
13/2/2017
09:04
13th feb Liberum buy tp 5100p cut from 5200p
philanderer
10/2/2017
10:23
10th feb Cantor buy tp 4900p up from 4700p
philanderer
08/2/2017
20:13
AstraZeneca (AZN) Said to Weigh Sale of Some Drugs in U.S., Europe - Bloomberg AstraZeneca (NYSE: AZN) is weighing the sale of older treatments in the U.S. and Europe, according to Bloomberg, citing people familiar with the matter. Drugs under consideration include Pulmicort Respules for children's asthma and acid reflux drugs Nexium and Prilosec. It may also sell Arimidex for breast cancer and Atacand for high blood pressure. The value of the sale may range from a few hundred million to more than $1 billion. HTTP://www.streetinsider.com/
philanderer
07/2/2017
10:00
two more targets cut today... 7th feb JP Morgan neutral tp 4200p cut from 4300p 7th feb HSBC hold tp 4500p cut from 4700p
philanderer
06/2/2017
11:16
Sooner buy more GSK !!!
garycook
06/2/2017
11:14
Astrazeneca still a 'buy' after profit warning, says Deutsche Bank HTTP://www.sharecast.com/news/astrazeneca-still-a-buy-after-profit-warning-says-deutsche-bank/25517112.html
philanderer
06/2/2017
09:09
6th feb ShoreCap sell tp 4000p downgrade from hold 6th feb Deutsche buy tp 5500p cut from 6000p
philanderer
03/2/2017
17:43
updated: 3rd feb Credit Suisse underperform tp 4000p 3rd feb UBS buy tp 5000p 3rd feb JP Morgan neutral tp 4300p 2nd feb ShoreCap hold - 2nd feb Liberum buy tp 5200p 2nd feb Cantor buy tp 4700p 2nd feb ++++++ Results ++++++
philanderer
02/2/2017
21:09
Easy ones first.....Wimbledon final 2022?......that'll be Federer,he'll only be 40.
steeplejack
02/2/2017
13:57
worth a buy here looks good
nw99
Chat Pages: 411  410  409  408  407  406  405  404  403  402  401  400  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170222 08:32:41